Atria Investments Inc Buys Shares of 13,300 Anavex Life Sciences Corp. (NASDAQ:AVXL)

Atria Investments Inc purchased a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,300 shares of the biotechnology company’s stock, valued at approximately $76,000.

A number of other large investors have also made changes to their positions in AVXL. Balentine LLC acquired a new stake in shares of Anavex Life Sciences in the 3rd quarter worth approximately $115,000. Forum Financial Management LP purchased a new stake in shares of Anavex Life Sciences in the third quarter valued at about $200,000. China Universal Asset Management Co. Ltd. grew its position in shares of Anavex Life Sciences by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 6,366 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of Anavex Life Sciences by 10.3% during the 3rd quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 4,442 shares in the last quarter. Finally, Creative Planning raised its position in shares of Anavex Life Sciences by 54.2% during the 3rd quarter. Creative Planning now owns 39,871 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 14,010 shares during the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Anavex Life Sciences in a research report on Monday, November 4th.

Anavex Life Sciences Price Performance

Shares of NASDAQ AVXL opened at $9.11 on Monday. The company has a market cap of $772.53 million, a PE ratio of -18.22 and a beta of 0.60. The company has a 50-day simple moving average of $6.40 and a 200-day simple moving average of $5.55. Anavex Life Sciences Corp. has a 12 month low of $3.25 and a 12 month high of $10.45.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.